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Wider use of pharmacological models would facilitate the
development of new drugs for Alzheimer’s disease (AD).
The two main models currently used are based on the
cholinergic and glutamatergic hypotheses of AD. Although
they lead to some of the attention and memory impair-
ment observed in AD, they do not fully reproduce the AD
pattern. The few studies that used a combination modeling
approach, ie, the simultaneous administration of several
drugs with the aim of impairing several neurotransmitters
or different aspects of a single system, have reported no or
marginal cumulative effect. On the basis of current under-
standing of glutamate and acetylcholine involvement in
AD pathophysiology, we suggest that models using selec-
tive muscarinic-1 (M1) receptor blockers would better mimic
the status of the cholinergic system in AD. This kind of
model might be suitable for the assessment of drugs that
do not act directly on the cholinergic system.
ll the professionals involved are convinced that
finding effective treatments for Alzheimer’s disease (AD)
should be a priority for the pharmaceutical industry.AD
is a wonderful challenge for industry.However,research
and development in this field can also be a risky busi-
ness.There is currently no consensus on the pathophys-
iology of AD on which drug development can rely.The
clinicopathologic picture that we call AD may actually
be a syndrome, with many possible causes.As a conse-
quence,we still have no reliable,positive diagnostic test
that can be applied on an individual basis, which leads
to the risk of recruiting very heterogeneous patient pop-
ulations for clinical trials. The low response rate to
acetylcholine esterase inhibitors probably illustrates
these uncertainties.
Before starting expensive trials,pharmaceutical compa-
nies clearly need to assess the validity of the underlying
concept in the early phases of development.Part of the
answer can come from animal models. However, if a
pharmacological effect is observed, it must still be con-
firmed in humans.
Some advocate early administration to patients,but this
is not necessarily the simplest method.The risk of het-
erogeneous recruitment to clinical trials is an important
point. If the goal is to measure clinical improvement,
the drug will probably be administered for a long peri-
od of time. If the trial intends to assess changes in sur-
rogate markers, these must be defined. Recruiting
groups homogeneous for a selected marker can be dif-
ficult and time-consuming, and at this phase of devel-
opment we need to go as fast as possible.Keeping pools
of untreated patients at hand for this purpose, and
depriving them of currently available drugs,is ethically
questionable.
It is easier and faster to work with healthy volunteers,
and, better, young healthy volunteers.This requires the
use of models, in which the putative drug is evaluated
for its ability to reverse either induced cognitive impair-
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Pharmacological aspectsment or associated markers (using electroencephalo-
gram [EEG],positron emission tomography [PET] scan,
and functional magnetic resonance imaging [fMRI]
changes),or both.
The scopolamine model
Scopolamine is a nonselective,
1 competitive
2 muscarinic
receptor blocker.The scopolamine model has its roots
in the cholinergic hypothesis of aging and AD, and has
played a major role in its construction, which we will
recall briefly here.
From the beginning of the 20th century until the mid-
fifties, scopolamine was used in obstetrics to induce a
twilight state and amnesia during childbirth.
3 In the six-
ties and seventies,it became obvious that regions rich in
cholinergic afferents, such as the hippocampus, were
involved in memory processes (see reference 4 for a
review). In 1965, acetylcholine esterase activity was
shown to be lowered in AD.
5 In 1974, Drachman and
Leavitt
6 administered scopolamine to healthy young vol-
unteers,who then displayed a memory profile very close
to that observed in elderly people.
Two to three years later, three independent research
teams
7-9 reported a decreased activity of choline acetyl-
transferase (CAT), the enzyme responsible for acetyl-
choline (Ach) synthesis, in the cortex of AD patients.
This decrease was shown to be correlated with brain
lesions and clinical status.
10,11 It was soon found that neu-
ronal loss occurs in the forebrain basal nucleus of Meyn-
ert
12 and medial septal nucleus,
13 which are the source of
neocortical and hippocampal cholinergic afferent fibers,
respectively.
14-16 In its early version,
4 the cholinergic
hypothesis stated nothing about etiological factors, did
not address the additional roles that ACh dysfunction
may play in other neurobehavioral disturbances of aging
and dementia, and did not imply any exclusive or soli-
tary involvement of the cholinergic system in age-relat-
ed memory loss. It was a kind of “black box” model, in
which an unknown pathophysiological process induces
deficiency in various neurotransmission pathways
thought to be responsible for the cognitive and behav-
ioral aspects of aging and dementia. Despite obvious
shortcomings (see references 17–20 for review and dis-
cussion), the cholinergic hypothesis legitimized the
development of the cholinergic drugs we prescribe
today and the administration of scopolamine as a model
of investigation for AD research.
The scopolamine model was used in cognitive research
to study the clinical correlates of ACh deficiency (see
reference 21 for a review).It was applied to elderly sub-
jects and AD patients
22-33 as a marker of cholinergic sen-
sitivity,with the purpose of improving the diagnosis and
staging of the disease.It failed,however,to predict cog-
nitive decline on the basis of the subjects’ sensitivity.
34
Animal studies assessing the reversal of scopolamine-
induced memory impairment by various compounds 
are too numerous to be cited exhaustively. This
approach has also been used in humans with the follow-
ing molecules: physostigmine,
35-40 velnacrine,
40 choline,
41
RO 15-1788,
39 moclobemide,
42,43 RU 41656,
44 L-α -glyc-
erylphosphorylcholine,
45 oxiracetam,
46 aniracetam and
piracetam,
47 tenilsetam,
48 BMY 21502,
49 D-cycloserine,
50
SDZ ENS-163,
51 and ZK-93426.
52 However, the scopol-
amine model has not become a standard tool in the
early assessment of drugs.
One reason for this is that the cognitive changes induced
by scopolamine do not really mimic the AD picture.The
details of the differences listed in Figure 1 (based on ref-
erences 28, 40, and 53–63) are open to discussion, but
there is a general agreement on the fact that,as Wesnes
40
wrote,all the scopolamine-induced deficiencies are also
observed in AD,while the reverse is not always true.The
same is observed in neurological investigations. The
electrophysiological effects of scopolamine (reviewed in
reference 64) are close on EEG and similar on visual
evoked potentials to those of AD. In PET
65-68 and single
photon emission computed tomography (SPECT)
69
studies,scopolamine induces cerebral blood flow (CBF)
and glucose metabolism changes, which are sometimes
divergent and region-specific, but in all cases different
from the pattern observed in AD.
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Selected abbreviations and acronyms
ACh acetylcholine
AChR acetylcholine receptor
AD Alzheimer’s disease
APP amyloid precursor protein
 A  -amyloid
CAT choline acetyltransferase
NMDA N-methyl-D-aspartate
NPY neuropeptide Y249
The ketamine model
Ketamine is a noncompetitive N-methyl-D-aspartate
(NMDA) receptor antagonist.
70,71 Its administration in
order to produce a model is the correlate of the gluta-
matergic hypothesis of AD (reviewed in reference 72).
Two, apparently opposite, glutamatergic hypotheses
have been proposed.The excitotoxic hypothesis states
that there is a glutamatergic hyperactivity in AD.
Domoic acid poisoning in humans was responsible for
irreversible memory loss.
73 Neuronal
74 and astroglial
75
glutamate transporter dysfunction in AD could result
in excess glutamate in the synaptic cleft and in excito-
toxic neuronal damage.This hypothesis is consistent
with the beneficial effects of memantine
76 and lamot-
rigine
77 in AD patients. Some findings provide a link
with the histopathological lesions that are the hallmarks
of AD. Kainic acid injection in the rat leads to
decreased neuronal amyloid precursor protein (APP)
695 mRNA owing to neuronal death, and increased
astrocytic APP 770 mRNA,
78 which has been found
selectively increased in AD in comparison with other
neurodegenerative disorders
79 and associated with
plaques.
80 β -Amyloid sensitizes neurons to glutamate
toxicity
81 and also enhances glutamate release by
macrophages.
82 Furthermore,in neuronal culture,gluta-
mate was shown to enhance tau gene expression
83 and
induce paired helical filaments similar to those found in
AD.
84 The hypoglutamatergic hypothesis has been
extensively reviewed elsewhere (see Newcomer et al,in
this issue).The ketamine model is its application. Ket-
amine is mainly used in the field of schizophrenia
research to provoke psychotomimetic as well as cogni-
tive effects.
85-94These studies did not all assess the same
functions or use the same paradigm to assess a particu-
lar function.Despite this limitation,when these studies
are summarized and the profile of ketamine effects
compared with that of AD (Figure 1),
60-63 the situation is
the same as that for the scopolamine model: the func-
tions affected by ketamine are affected in AD, but the
reverse is not necessarily the case.
Future directions 
The two main models proposed thus lead to some of
the attentional and memory impairment observed in
AD, but do not fully reproduce the AD pattern.Two
options are therefore possible. Since multiple neuro-
transmitter systems are affected in AD,it has been sug-
gested
95 that combination modeling through simulta-
neous administration of drugs that impair several neu-
rotransmitters or different aspects of a single system
could mimic the AD pattern more closely. The few
published studies on this strategy add mecamylamine,
96
m-chlorophenylpiperazine (mCPP),
97 metergoline, or
haloperidol
98 to scopolamine, and report no
98 or mar-
ginal
96,97 cumulative effect.Although NMDA antago-
nists were shown to potentiate the amnesic effect of
scopolamine in the rat,
58 no study on this combination
in humans has been published to date. Beyond the
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Figure 1. Memory dysfunction in Alzheimer’s disease (AD) and
after scopolamine or ketamine. 
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weakness of their effects,combined models are so com-
plex that they become difficult to understand—and
particularly difficult to manipulate—in the assessment
of cognitive enhancers. Another method is to take
advantage of the recent advances in our understanding
of AD. Currently available data support the view that
neuronal and synaptic loss,rather than secondary neu-
rotransmission disruption, is most likely responsible
for cognitive changes in AD.
99They also allow attempts
to integrate neurotransmitter changes into a more
comprehensive theoretical framework.The cholinergic
hypothesis in its current version (Figure 2) focuses on
the reciprocal modulatory influences of cholinergic
transmission and APP processing (reviewed in refer-
ences 100 and 101). β -Amyloid (β A) is known to be
neurotoxic at high (micromolar) concentrations.
102 In
vitro, soluble β A at picomolar to nanomolar levels is
not toxic but does inhibit synthesis and stimulated
release of ACh.
103-105 Studies on the possible inhibitory
effect of β A on CAT activity
104-106 gave divergent
results.β A appears to exert its effect on ACh synthesis
and release through depletion of ACh precursors. It
has been shown to disrupt the activity of pyruvate
dehydrogenase,
106 which generates acetyl coenzyme A
(CoA) from pyruvate and was found to be decreased
in the cortex of AD patients,
107 and to inhibit high-
affinity choline uptake.
104 This could have an indirect
neurotoxic effect, since cholinergic neurons deprived
of choline have been shown to break down phos-
phatidylcholine from intracellular organelle mem-
branes to provide additional choline.
108
Although there is no general consensus (see reference
109 for review), it is thought that postsynaptic mus-
carinic M1 acetylcholine receptor (AChR) density is
unchanged in AD, while those of presynaptic M2 and
nicotinic AChRs are reduced.
110,111 It has been shown that
activation of protein kinase C through M1 (and M3)
AChRs lowers β A production by favoring the nonamyl-
oidogenic processing of APP.
112,113 Despite their un-
changed density,M1 receptors could be dysfunctional
114,115
because of defective coupling to Gq/11 proteins.
116 This
could lead to increased β A production,which would fur-
ther impair M1 AChR signal transduction.
117 M1
AchR–G protein uncoupling could also favor protein
tau phosphorylation and thus paired helical filament
formation through disinhibition of mitogen-activated
protein (MAP) kinases
118 and decreased efficiency of tau
dephosphorylation.
119
Despite the uncertainties that remain,it is clear that the
cholinergic deficiency can no longer be seen as a late
consequence of neuropathological changes, but at least
as a contributor to the cascade of events leading to full-
blown dementia.
The glutamatergic hypothesis has also been revisited.
Its current version (see Newcomer et al, in this issue)
reconciles the former hyper- and hypoglutamatergic
hypotheses by proposing a two-stage process.
• In the first stage, β A increases the sensitivity of
NMDA receptors to normal concentrations of gluta-
mate, leading to destruction of NMDA-bearing
GABAergic (GABA: gamma-aminobutyric acid),
noradrenergic (NE),and serotonergic (5-HT) neurons,
which have an inhibitory action on basal forebrain
cholinergic, anterior thalamic glutamatergic, and cor-
tical neuropeptide Y (NPY) neurons either directly
(GABA,NE) or through activation of GABA neurons
(5-HT).
• This loss of inhibition leads to hyperstimulation of cor-
tical and corticolimbic neurons, which then degener-
ate, as do the hyperactive cholinergic, glutamatergic,
and NPY neurons.
This suggests that for both cholinergic and gluta-
matergic neurons, the hypoactive, symptomatic stage
is preceded by a hyperactive one.These new versions
of the cholinergic and glutamatergic hypotheses make
it necessary for us to reappraise our models.The goal
of an acute pharmacological model is to transiently
reproduce the hypoactive,symptomatic stage.Accord-
ing to the scheme proposed by Newcomer et al else-
where in this issue, NMDA blockers induce transient
hyperactivity of basal forebrain cholinergic, anterior
thalamic glutamatergic, and cortical NPY neurons. It
is likely that the mechanism by which acute adminis-
tration of NMDA blockers produces memory impair-
ment is different and does not involve the two-stage
sequence proposed as a chronic model.The finding
that pretreatment with haloperidol reduces ketamine-
induced impairment in executive cognitive functions
91
nonetheless suggests that the cognitive effect of
NMDA blockade is indirect and nonselective. Higher
selectivity, which would also avoid psychotomimetic
symptomatology, might be achieved by acting down-
stream of the NMDA receptor.For the particular pos-
terior cingulate and retrosplenial region, the best
choice would be to give m3 and/or kainate receptor
blockers.Another target of choice is the hippocampus,
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in which the most common muscarinic receptor is the
m1 subtype;the m2 subtype represents 15% and the m3
subtype globally less than 12%.
120 Moreover, specific
blockade of the m1 receptors would best reproduce
their status in AD, where they are hypostimulated
(because of presynaptic neuronal loss) and dysfunc-
tional.The only molecule which is more or less selec-
tive for the m1 receptor
121 and available for human use
is pirenzepine. It is said to cross the blood–brain bar-
rier poorly,
122 but very few studies have assessed its
central effects in man
123-125 and we think it deserves fur-
ther study.
Do neurotransmitter-based pharmacological
models have a future?
The way the cognitive symptoms are produced in AD is
complex and many therapeutic strategies already in
development address β A metabolism and toxicity,
126-128
rather than cholinergic deficiency.However, D-cycloser-
ine, which does not act on the cholinergic system but
modulates the NMDA receptor, has been shown to
attenuate the effect of scopolamine on memory.
50
Moclobemide, a selective monoamine oxidase A
(MAOA) inhibitor,
42,43 and thyrotropin-releasing hor-
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Figure 2. The cholinergic hypothesis today. 
Amyloid precursor protein (APP) is processed either by α -secretase into a nonamyloidogenic pathway or by β - and γ -secretases to produce β -
amyloid peptide (β A). β A could decrease choline acetyltransferase (CAT, the acetylcholine synthesis enzyme) activity. It lowers the
availability of the substrates for acetylcholine (ACh) synthesis by impairing high-affinity choline uptake and acetyl coenzyme A (acetyl CoA)
production; therefore ACh release is also diminished. Choline deprivation could initiate the so-called “autocannibalism” process through
which ACh neurons break down membrane phosphatidylcholine to increase choline availability. Autocannibalism could be partly
responsible for neuronal loss in the basal nucleus of Meynert (BNM), medial septal nucleus (S), and nucleus of the diagonal band of Broca
(DB), and for the observed decrease in muscarinic M2 and nicotinic (N) receptor densities, which are mainly presynaptic. Muscarinic M1
receptors are mainly postsynaptic and their density is not affected in Alzheimer’s disease. However, they are probably dysfunctional
because of receptor–G protein uncoupling, with two consequences: (i) lowered M1 signal transduction favors the amyloidogenic APP
processing pathway, which further aggravates uncoupling; and (ii) through loss of inhibition of mitogen-activated protein (MAP) kinase,
which results in increased tau protein phosphorylation, and inhibition of phosphatase, which results in a lesser dephosporylation of tau, it
favors the formation of paired helical filaments (PHF).mone (TRH)
129 were also able to partly reverse the
scopolamine-induced deficits. In the animal, the same
has been observed with estrogens
130 and GM1 ganglio-
sides.
131 Given these data and the current view that we
have on the involvement of the cholinergic deficiency,
it is very possible that new compounds, which do not
act directly on the cholinergic system, could be effec-
tive on cholinergic models. Neurotransmitter-based
models still have a place in our armamentarium,
although efforts should be made to develop other
approaches.
Conclusion
Whatever the model chosen, we must admit that it is
impossible to reproduce the full AD cognitive pattern.
Instead,we can try to produce some aspects of memory
impairment,which is considered as the core symptom of
the disease.The method used should be as simple and
selective as possible in order to allow its manipulation.
Selective ligands are currently in development
132;accel-
erating the toxicological studies of these compounds
could allow us to work this way in the near future. ❑
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Modelos farmacológicos en la investigación de la
enfermedad de Alzheimer
Un empleo más generalizado de modelos farma-
cológicos facilitaría el desarrollo de nuevos fár-
macos para la enfermedad de Alzheimer (EA).
Los dos modelos principales actualmente en uso
se basan en las hipótesis colinérgica y glutama-
térgica de la EA. Aunque ambos modelos se
orientan hacia algunos de los deterioros en la
atención y en la memoria observados en la EA,
ellos no reproducen totalmente el patrón de la
EA. Los pocos estudios que utilizan una combi-
nación de modelos (ej. la administración simultá-
nea de varios fármacos con el objetivo de afectar
algunos neurotransmisores o diferentes aspectos
de un sistema único) no han informado de nin-
gún efecto significativo, a lo más el efecto acu-
mulativo es marginal. De acuerdo con el conoci-
miento actual del compromiso del glutamato y
de la acetilcolina en la fisiopatología de la EA,
nosotros sugerimos que los modelos que emple-
an bloqueadores selectivos de los receptores
muscarínicos-1 (M1) podrían imitar mejor la situa-
ción del sistema colinérgico en la EA. Esta clase
de modelo sería conveniente para la evaluación
de fármacos que no actúan directamente en el
sistema colinérgico.
Modèles pharmacologiques dans la maladie
d’Alzheimer 
Le recours plus fréquent aux modèles pharmaco-
logiques devrait faciliter le développement de
nouvelles thérapeutiques dans la maladie d’Alz-
heimer (MA). Les deux principaux modèles utilisés
actuellement sont fondés sur l’hypothèse d’une
implication du système cholinergique et du systè-
me glutamatergique dans la maladie d’Alzheimer.
Mais si l’on peut observer dans ces modèles l’ap-
parition de certains des troubles de l’attention et
de la mémoire observés au cours de la MA, ils ne
génèrent pas la totalité des manifestations de la
pathologie. Dans les quelques études qui ont uti-
lisé un modèle combinant l’administration simul-
tanée de plusieurs molécules dans le but d’altérer
différents neurotransmetteurs ou différentes
étapes d’un même système, l’effet cumulatif obte-
nu a été nul ou négligeable. En nous appuyant sur
nos connaissances actuelles de l’implication du
glutamate et de l’acétylcholine dans la physiopa-
thologie de la MA, nous proposons d’utiliser des
inhibiteurs sélectifs des récepteurs muscari-
niques–1 (M1) pour reproduire au mieux l’état du
système cholinergique dans la MA. Ce type de
modèle pourrait permettre d’évaluer des molé-
cules qui n’agissent pas directement sur le système
cholinergique.Pharmacological models in Alzheimer’s disease research - Gilles and Ertlé Dialogues in Clinical Neuroscience - Vol 2 . No.3 . 2000
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